Effect of enalapril on blood pressure, renal function, and the renin-angiotensin-aldosterone system in cats with autosomal dominant polycystic kidney disease

American Journal of Veterinary Research

Volumn 60, Issue 12, 1999, Pages 1516-1525

  Miller, Rita H ^a   Lehmkuhl, Linda B ^a   Smeak, Daniel D ^a   Dibartola, Stephen P ^a   Radin, Judith ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ENALAPRIL; RENIN;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR AUTOREGULATION; CAT DISEASE; CONTROLLED STUDY; HYPERTENSION; KIDNEY POLYCYSTIC DISEASE; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CAT DISEASES; CATS; ENALAPRIL; FEMALE; KIDNEY; KIDNEY FUNCTION TESTS; MALE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RENIN-ANGIOTENSIN SYSTEM;

ANIMALIA; FELIS CATUS;

EID: 0032731003     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Biller DS, DiBartola SP, Eaton KA, et al. The inheritance of polycystic kidney disease in Persian cats. J Hered 1996;87:1-5.
2. Lulich JP, Osborne CA, Walter PA, et al. Feline idiopathic polycystic kidney disease. Compend Contin Educ Pract Vet 1988;10:1029-1041.
3. Crowell WA, Hubbell JJ, Riley JC. Polycystic renal disease in related cats. J Am Vet Med Assoc 1979;175:286-288.
4. Chapman AB, Schrier RW. Pathogenesis of hypertension in autosomal dominant polycystic kidney disease. Semin Nephrol 1991;11:653-660.
5. Gabow PA. Autosomal dominant polycystic kidney disease. Am J Kidney Dis 1993;22:511-2.
6. Hayashi T, Mochizuki T, Reynolds T, et al. Characterization of the exon structure of the polycystic kidney disease 2 gene (PKD2). Genomics 1997;44:131-136.
7. Peters DJM, Sandkuijl LA. Genetic heterogeneity of polycystic kidney disease in Europe. Contrib Nephrol 1992;97:128-139.
8. Eaton KA, Biller DS, DiBartola SP, et al. Autosomal dominant polycystic kidney disease in Persian and Persian-cross cats. Vet Pathol 1997;34:21-30.
9. Hansson L, Karlander LE, Lundgren W, et al. Hypertension in polycystic kidney disease. Scand J Urol Nephrol 1974;101: 238-247.
10. Milutinovic J, Fialkow PJ, Agodoa LY, et al. Autosomal dominant polycystic kidney disease: symptoms and clinical findings. Q J M 1984;53:511-522.
11. Gabow PA, Chapman AB, Johnson AM, et al. Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 1990;38:1177-1180.
12. Barrett BJ, Foley R, Morgan J, et al. Differences in hormonal and renal vascular responses between normotensive patients with ADPKD and unaffected family members. Kidney Int 1994;46: 1118-1123.
13. Harrap SB, Davies DL, Macnicol AM, et al. Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. Kidney Int 1991;40: 501-508.
14. Watson ML, Macnicol AM, Allan PL, et al. Effects of angiotensin converting enzyme inhibition in adult polycystic kidney disease. Kidney Int 1992;41:206-210.
15. Gabow PA, Johnson AM, Kaehny WD, et al. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 1992;41:1311-1319.
16. Iglesias CG, Torres VE, Offord KP, et al. Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935-1980. Am J Kidney Dis 1983;2:630-639.
17. Calabrese G, Vagelli G, Cristofano C, et al. Behavior of arterial pressure in different stages of polycystic kidney disease. Nephron 1982;32:207-208.
18. Florijn KW, van-Saase JL, Breuning MH, et al. Autosomal-dominant polycystic kidney disease and hypertension: a review. Contrib Nephrol 1992;97:71-92.
19. Chapman AB, Johnson A, Gabow PA, et al. The reninangiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990;323;1091-1096.
20. Littman MP. Spontaneous systemic hypertension in 24 cats. J Vet Intern Med 1994;8:79-86.
21. Lesser M, Fox PR, Bond BR. Assessment of hypertension in 40 cats with left ventricular hypertrophy by Doppler-shift sphygmomanometry. J Small Anim Pract 1992;33:55-58.
22. Kobayashi DL, Peterson ME, Graves TK, et al. Hypertension in cats with chronic renal failure or hyperthyroidism. J Vet Intern Med 1990;4:58-62.
23. Jensen J, Henik RA, Brownfield M, et al. Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease. Am J Vet Res 1997;58:535-540.
24. Henik RA, Snyder PS, Volk LM. Treatment of systemic hypertension in cats with amlodipine besylate. J Am Anim Hosp Assoc 1997;33:226-34.
25. Snyder PS. Amlodipine: A randomized, blinded clinical trial in 9 cats with systemic hypertension. J Vet Intern Med 1998;12: 157-162.
26. National Research Council. Nutrient requirements of cats 1986. Washington, DC: National Research Council, 1986;17.
27. Brown SA, Langford K, Tarver S. Effects of certain vasoactive agents on the long-term pattern of blood pressure, heart rate, and motor activity in cats. Am J Vet Res 1997;58:647-652.
28. Evans KL, Smeak DD, Couto CG, et al. Comparison of two indwelling central venous acces catheters in dogs undergoing fractional radiotherapy. Vet Surg 1994;23:135-142.
29. Smeak DD. Chinese finger trap suture pattern for catheter fastening to the skin. J Am Anim Hosp Assoc 1990;26:215-218.
30. Haber E, Koerner T, Page B, et al. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab 1969;29:1349-1355.
31. Dow SW, Fettman MJ, LeCouteur RA, et al. Potassium depletion in cats: renal and dietary influences. J Am Vet Med Assoc 1987;191:1569-1575.
32. Radin MJ, Jenkins JE, McCune SA, et al. Effects of enalapril and clonidine on glomerular structure, function, and atrial natriuretic peptide receptors in SHHF/Mcc-cp rats. J Cardiovasc Pharmacol 1992;19:464-472.
33. Theisen SK, DiBartola SP, Radin J, et al. Muscle potassium content and potassium gluconate supplementation in normokalemic cats with naturally occurring chronic renal failure. J Vet Intern Med 1997;11:212-217.
34. Brockway BP, Mills PA, Azar SH. A new method for continuous chronic measurement and recording of blood pressure, heart rate and activity in the rat via radiotelemetry. Clin Exp Hypertens 1991;13:885-895.
35. Truett A ,West DB. Validation of a radiotelemetry system for continuous blood pressure and heart rate monitoring in dogs. Lab Anim Sci 1995;45:299-302.
36. Brown SA. Ambulatory blood pressure measurements in cats, in Proceedings. 13th Annu Vet Med Forum 1995; 503-504.
37. Valvo E, Gammaro L, Bedogna V, et al. Hypertension in polycystic kidney disease. Contrib Nephrol 1987;54:95-102.
38. Sealey JE, Campbell GA, Preibisz JJ. Hormone assays. In: Laragh JH, Brenner BM, eds. Hypertension pathophysiology, diagnosis, and management. New York: Raven Press, 1990;1443-1460.
39. Gabow PA, Ikle DW, Holmes JH. Polycystic kidney disease: prospective analysis of nonazotemic patients and family members Ann Intern Med 1984;101:238-247.
40. Parfrey PS, Bear JC, Morgan J, et al. The diagnosis and prognosis of autosomal dominant polycystic kidney disease. N Engl J Med 1990;323:1085-1090.
41. Nash DA. Hypertension in polycystic kidney disease without renal failure. Arch Intern Med 1977;137:1571-1575.
42. Brod J, Bahlmann J, Cachovan M, et al. Mechanisms for the elevation of blood pressure in human renal disease. Hypertension 1982;4:839-844.
43. Valvo E, Gammaro L, Tessitore N, et al. Hypertension of polycystic kidney disease: mechanisms and hemodynamic alterations. Am J Nephrol 1985;5:176-181.
44. Danielsen H, Nielsen AH, Pedersen EB, et al. Exaggerated natriuresis in adult polycystic kidney disease. Acta Med Scand 1986;219:59-66.
45. Bell PE, Hossack KF, Gabow PA, et al. Hypertension in autosomal dominant polycystic kidney disease. Kidney Int 1988;34: 683-690.
46. Sorensen SS, Glud TK, Sorensen PJ, et al. Change in renal tubular sodium and water handling during progression of polycystic kidney disease: relationship to atrial natriuretic peptide. Nephrol Dial Transplant 1990;5:247-257.
47. Torres VE, Wilson DM, Burnett J, Jr, et al. Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease. Mayo Clin Proc 1991;66: 1010-1017.
48. Laragh JH. Renin profiling for diagnosis, risk assessment, and treatment of hypertension. Kidney Int 1993;44:1163-1175.
49. Yu S, Morris JG. The minimum sodium requirement of growing kittens defined on the basis of plasma aldosterone concentration. J Nutr 1997;127:494-501.
50. Glorioso N, Troffa C, Laragh JH, et al. The cat: an animal model for studies of inactive reniri. Am J Physiol 1987;25: E509-E518.
51. Brown SA. Antihypertensive therapy: why, when, what, how much?, in Proceedings. 15th Annu Vet Med Forum, 1997; 497-498.
52. Biller DS, Chew DJ, DiBartola SP. Polycystic kidney disease in a family of Persian cats. J Am Vet Med Assoc 1990;196:1288-1290.
53. Franz KA, Reubi FC. Rate of functional deterioration in polycystic kidney disease. Kidney Int 1983;23:526-529.
54. Ritz E, Zeier M, Geberth S, et al. Autosomal dominant polycystic kidney disease (ADPKD) - mechanisms of cyst formation and renal failure. Aust N Z J Med 1993;23:35-41.
55. Adams LG, Polzin DJ, Osborne CA, et al. Comparison of fractional excretion and 24-hour urinary excretion of sodium and potassium in clinically normal cats and cats with induced chronic renal failure. Am J Vet Res 1991;52:718-722.
56. Finco DR, Barsanti JA, Brown SA. Solute fractional excretion rates. In: Kirk RW, Bonagura JD, eds. Current veterinary therapy XI. Philadelphia: WB Saunders Co, 1992; 818-829.
57. Finco DR, Brown SA, Barsanti JA, et al. Reliability of using random urine samples for "spot" determination of fractional excretion of electrolytes in cats. Am J Vet Res 1997;58:1184-1187.
58. Schmidt M, Krieger JP, Devissaguet M, et al. Renal effects of perindoprilat, an angiotensin-converting enzyme inhibitor, in the anesthetized dog. J Cardiovasc Pharmacol 1989;13:283-290.
59. Heller J, Kramer HJ, Horacek V. Comparative effects of the angiotensin II receptor blocker EXP 3174 and of the angiotensin-converting enzyme inhibitor captopril on renal glomerular hemodynamics in the dog. Kidney Blood Press Res 1997;20:391-397.
60. Nishiyama S, Kanno K, Yoneda H, et al. Effects of the new angiotensin-converting enzyme inhibitor imidapril on renal hemodynamics and function in anesthetized dogs. Arzneimittelforschung 1992;42:451-456.
61. Chapman AB, Gabow PA, Schrier RW Reversible renal failure associated with angiotensin-converting enzyme inhibitors in polycystic kidney disease. Ann Intern Med 1991;115:769-773.
62. Chapman AB, Schrier RW, Gabow PA. Polycystic kidney disease and angiotensin-converting enzyme inhibitors - response to letter to the editors. Ann Int Med 1992;117:90.
63. Susick RL, Dominick MA, Ulloa HM, et al. Renal morphology and function in dogs after treatment with the angiotensin-converting enyzme inhibitor quinapril. J Cardiovasc Pharmacol 1994;23: 275-282.
64. La Rocca PT, Squibb RE, Powell ML, et al. Acute and subchronic toxicity of a nonsulfhydryl angiotensin-converting enzyme inhibitor. Toxicol Appl Pharmacol 1986;82:104-111.
65. Fyhrquist F, Rosenlof K, Gronhagen-Riska C, et al. Is renin substrate an erythropoietin precursor? Nature 1984;308:649-652.